MS Trials Dr Anthony Fok Neurologist and Neuroophthalmologist

MS Trials Dr Anthony Fok Neurologist and Neuro-ophthalmologist

Research and Development

IL-37 Studying the role of a Interleukin-37 in inflammatory diseases Thought: IL-37 is an inhibitor of inflammation Check IL-37 levels in patients with inflammatory diseases and compare to patients without diseases Need: Consent and blood taken. Future: this may lead to drug development

Vitamin D is thought to play a role in MS Prev. ANZ Patients with a first clinical attack – Clinically isolated Syndrome Test different doses of Vitamin D 3 See whether it can delay or prevent a second episode that would lead to diagnosis of MS Double blind Placebo controlled Treatment for 12 months Collect blood and urine Safety Efficacy/safety and compare to other drug

ESTEEM trial Phase IV trial for Tecfidera (dimethyl Fumarate) Include: all patients starting Tecfidera Followup every 6 months Monitor adverse effects You need to complete questionnaires at each clinic visit – can be done online

AFFINITY STUDY Multicentre, randomised, double blinded placebo controlled study Relapsing Remitting MS Add on therapy to otherapies - Interferon (beta 1 a, beta 1 b, beta 1 a) - Dimethyl fumerate - Nataluzimab Dx: RRMS EDSS 2 -6 MS disease duration <20 years Relapse within 24 months and new lesions on MRI

Ask your friendly neurologist or MS nurse